Introduction: infection due to multidrug-resistant microorganisms is a growing threat in healthcare settings. Acinetobacter species specifically
Introduction
The genus Acinetobacter comprises of non-motile gram-negative coccobacilli bacteria. The colonies are 1 to 2mm, non-hemolytic, mucoid, smooth and round on sheep's blood agar after 24 hours of incubation at 37ºC (Figure 1 ) [1] [2] [3] . Most species in this genus have emerged as common pathogens causing community as well as hospital-acquired infections [4, 5] . Hospital-acquired infections are common among patients admitted in the intensive care unit (ICU) and those patients not admitted in the ICU but are immunocompromised.
Infections linked to these species include wound infections, urinary tract infections, pneumonia and bacteremia subsequent to trauma, urinary catheters, mechanical ventilators and central venous access catheters respectively. These infections increase the length of hospital stay and risk of hospital death [6] . As a health concern, Acinetobacter associated infections are difficult to treat due to the natural tendency of acquisition and spread of multidrug-resistant strains among hospitalized patients and the organisms' different mechanism of antimicrobial resistance [7, 8] . This has contributed to the high morbidity and mortality rate ranging from 27% and 91% especially in immunocompromised patients in the last three decades [9] . Globally, the occurrence of MDR Acinetobacter, particularly A. baumannii has been reported through several epidemiological studies [10] with a documentation of 10-15% prevalence of Acinetobacter resistance to carbapenem, penicillins and fluoroquinolones [11, 12] . Acinetobacter species have relatively high resistance to carbapenems, even in countries with high level of awareness and vibrant national nosocomial infection surveillance with an overall low antibiotic resistance [11] [12] [13] .
However, carbapenems remain the treatment of choice for Acinetobacter infections [14] . In two separate studies conducted in Kenya, one study noted that 10% of community-acquired bacteremia was associated with Acinetobacter species [13] while in another study that recruited hospitalized patients, A. baumannii accounted for 0.9% in wound infections [15] . Management of nosocomial infections remains a challenge in healthcare settings due to the increasing resistance to antimicrobials [16] . Therefore the aim of this study was to evaluate the antimicrobial susceptibility of Acinetobacter species isolated from patients in Kenyatta National Hospital (KNH). Previous studies done in Kenya focused on critical care units, we however explored other hospital units.
Methods
This was a retrospective study. We analyzed electronic laboratory records of Acinetobacter isolates from clinical specimens analyzed between 2013 and 2015 at KNH microbiology laboratory. Identification and antimicrobial susceptibility data were retrieved from the VITEK-2 antimicrobial susceptibility system and exported to WHONET through BACLINK. Analysis was done using WHONET version 5.6 and IBM SPSS Statistics version 21. Identification of Acinetobacter isolates was done using VITEK-2 Gram Negative identification card (GN83). Clinical specimens were mainly tracheal aspirates, pus, and urine and were 
Results
The study analyzed 590 Acinetobacter isolates. Majority of the isolates were from male patients, 380 (52%). The isolates were mainly from tracheal aspirates (273; 46%), pus (130; 22%), urine (93; 16%) and blood (35; 6%). The specimen type for thirty-five (6%) of the isolates was unknown. Other isolates were obtained from peritoneal fluid, pleural fluid, cerebral spinal fluid and tissue. The most frequently isolated Acinetobacter species in this study was Acinetobacter baumannii (95%); the other isolates included Acinetobacter lwoffii (3%) and Acinetobacter haemolyticus (1%) ( Table 1) . Most of the isolates were obtained from samples collected from critical care unit (48%) and internal medicine (13%) with the least obtained from accident and emergency unit (9%) and burns unit (3%). Acinetobacter baumannii (n=560) showed high susceptibility to amikacin (77%) and poor susceptibility to tobramycin (37%), meropenem (27%), penicillins (1-27%), fluoroquinolones (13-24%), cephalosporins (0-11%) and trimethoprim-sulfamethoxazole (15%) (Figure 2 Acinetobacter baumannii isolates from tracheal aspirates, pus, and urine, showed high level of resistance to cephalosporins (65-85%), ciprofloxacin (69-76%) and moderate resistance to meropenem (51-59%) (Table 3 ). Isolates obtained from blood and other specimens had moderate resistance to cephalosporins (49-63%). Acinetobacter baumannii isolates from all specimens showed relatively high sensitivity to amikacin (77-89%). Antibiotic susceptibility varied with hospital units. High resistance to cephalosporins (65-86%) was seen in A. baumannii isolates from critical care unit, obstetrics and gynecology, internal medicine ward, accident and emergency, and surgery (Table 4) . In summary, A. baumannii was the most common species isolated and showed high susceptibility to amikacin (77%), high resistance to cephalosporins (89-100%), fluoroquinolones (76-87%) and meropenem (72%).
Discussion
In this study, we recorded 95% of Acinetobacter baumannii from all the samples analyzed. Other species were detected in low numbers Acinetobacter species. In our study, A. baumannii was resistant to meropenem (72%), compared to A. lwoffii and A. haemolyticus which recorded a high susceptibility of 100% and 75% respectively. Studies in other countries have however reported a slightly higher rate of resistance to meropenem (80-87%) in A. baumannii [28, 35, 36] . 
Conclusion
We report a high proportion of Acinetobacter isolates from samples obtained from critical care unit (48%) and tracheal aspirates (46%). 
What is known about this topic
• Acinetobacter is a non-motile, gram-negative coccobacillus that is found in the environment and colonizes the human body;
• Acinetobacter is a nosocomial pathogen associated with high mortality and morbidity especially among the immunocompromised patients;
• It's known for its intrinsic antibiotic resistance mechanism and the ability to rapidly acquire resistance genes.
What this study adds
• Acinetobacter baumannii was the most frequently isolated species and demonstrated high susceptibility to amikacin;
• Other species isolated were A. lwoffii and A. haemolyticus.
Both had high susceptibility to amikacin, meropenem, ciprofloxacin and gentamicin, but showed poor susceptibility to cephalosporins;
• Critical care units and tracheal aspirate had the highest proportion of A. baumannii isolates and recorded high resistance to commonly used antibiotics such as penicillins, fluoroquinolones, cephalosporins and meropenem.
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